VEGF、GRIM-19在86例肺癌患者组织中的表达水平及临床意义  

Expression levels of VEGF and GRIM-19 in the tissues of 86 cases of patients with lung cancer and their clinical significance

作　　者：曾尚干[1] 刘季春[1] 

机构地区：[1]南昌大学第一附属医院,江西330006

出　　处：《上海医药》2016年第17期45-47,60,共4页Shanghai Medical & Pharmaceutical Journal

基　　金：2015年江西省卫生厅科研计划(普通)课题,项目编号20154027

摘　　要：目的 :探讨VEGF、GRIM-19在肺癌患者组织中的表达水平及临床意义。方法 :选取我院2012年10月至2015年3月手术切除的86例肺癌患者的肿瘤组织及30例距肿瘤边缘5 cm以上的癌旁正常组织,应用免疫组化法检测所有组织中VEGF、GRIM-19的表达水平,统计分析二者表达水平与临床病理参数的关系。结果 :VEGF在肺癌组织中的阳性表达率(70.93%)明显高于癌旁组织(30.00%)(P<0.05)而GRIM-19的阳性表达率(44.19%)明显低于癌旁组织(83.33%)(P<0.05);VEGF的表达与临床分期、淋巴结转移有关,GRIM-19的表达与临床分期有关。结论 :VEGF、GRIM-19可作为肺癌病理分级诊断的重要标志物之一,并可通过肿瘤血管形成的生物学行为信息变化对肺癌患者的病情进展进行有效的监测。Objective： To discuss the expression levels of VEGF and GRIM-19 in the tissues of patients with lung cancer and their clinical significance. Methods： From October 2012 to March 2015, the tissues from 86 cases of patients with lung cancer who underwent surgical removal of the tumor and the normal tissues adjacent to more than 5 cm from the tumor margin from 30 cases were selected. The expression levels of VEGF and GRIM-19 in all tissues were detected by immunohistochemical method and the relationship between the expression levels and clinical pathological parameters was statistically analyzed. Results： Positive expression rate of VEGF was significantly higher in the lung cancer tissue （70.93%） than in the normal tissue adjacent to carcinoma （30.00%）, while that of GRIM-19 was significantly lower in the lung cancer tissue （44.19%） than in the normal tissue adjacent to carcinoma （83.33%） （P〈0.05）. The expression of VEGF was associated with clinical stages, lymph node metastasis while GRIM-19 only with clinical stage. Conclusion： VEGF and GRIM-19 can be used as one of the important markers of pathologic stage for lung cancer diagnosis and to effectively monitor the disease progression in patients with lung cancer based on the information change of the biological behavior of tumor angiogenesis.

关 键 词：肺癌 血管内皮生长因子 GRIM-19 

分 类 号：R734.2[医药卫生—肿瘤]